We are looking to gain insight into NP clinical practices in offering acute treatment to migraine sufferers. We would like to include only those Nurse Practitioners who have current experience in managing migraine patients as we would like to gather your feedback on your experience in clinical practice.
SUVEXX, a new acute treatment for migraine, is a convenient combination tablet of sumatriptan and naproxen sodium and is indicated for the acute treatment of migraine attacks with or without aura in adults.
CAMBIA, also indicated for the acute treatment of migraine, is a buffered diclofenac potassium oral solution that provides pain relief as early as 15 minutes.
The virtual meeting sessions will run from 6:00-7:30 pm PT: 7:00-8:30 pm MST: 8:00-9:30 pm CST Monday March 7th, 2022
Keynote speaker for both events - Christie Tait MN, NP-PHC Founder, Structure Clinic – Headache Wellness Center Clinician- Toronto Headache and Pain Clinic
➢ Review and discuss the pharmacokinetics and clinical evidence for SUVEXX & CAMBIA
➢ Understand your treatment strategies for migraines of different severity
➢ Obtain feedback on the likely patient settings in which you would prescribe SUVEXX and/or CAMBIA
For your participation you will receive an honorarium of $250.
How to Register:
Please register at the following link www.migrainemeetings.ca by February 28th, 2022.
Once you have registered online, you will receive confirmation of your registration by email.
Once you have registered online, you will also receive a Consulting Agreement by email. Please review, sign, and
return PRIOR to the event.
Once your signed Consulting Agreement has been received you will be sent an email from Brian Cousins from Biotext
with the log-in information for the meeting.
If you have any questions, please contact Theresa Furey at email@example.com or by phone at 905-317-6598.